MedTrace Logo

Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy

NCT02317393 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2020-07-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate the contribution of the imaging to the expression of intégrines αvβ3 for the characterization of the residual masses of non-seminoma tumors at the end of chemotherapy.

The investigators hope that the results of this first stage of the clinical trial come to consolidate the preclinical results obtained by the investigators team to characterizing the interest and the strong contribution of the use of a tracer resting on the expression of αvβ3 integrine for the diagnosis of simple necrosed mass at the end of the treatment of a non-seminoma tumor, so allowing to defer a surgery to about 40 % of the patients.

Conditions

  • Non-seminomatous Germ Cell Tumors
  • Metastasis

Interventions

OTHER

K5-RGD PET

Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy

OTHER

FDG

Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy

Sponsors & Collaborators

  • Centre Francois Baclesse

    lead OTHER

Principal Investigators

  • Nicolas AIDE, Dr · Centre François Baclesse, CAEN, France

  • Arnaud DOERFLER, Dr · CHU Côte de Nacre, CAEN, France

  • Pierre VERA, Dr · Centre Henri Becquerel, ROUEN, France

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2020-03-31
Completion
2020-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02317393 on ClinicalTrials.gov